<DOC>
	<DOCNO>NCT02006862</DOCNO>
	<brief_summary>This clinical observational study aim investigate efficacy olanzapine ( Villamos ® ) accordance instruction attach thereto standard clinical practice , follow physician patient . This multicenter , non- interventional observational study , 6-month period without prepare patient take usual medication . A total 3 schedule visit : Visit 1 Day 0 ( integration , base ) , Visit 2 month 3 Visit 3 month 6 ( = end treatment ) . The purpose study demonstrate efficacy safety olanzapine patient indicate . Will monitor recorded different concomitant therapy . The treatment patient individual designate physician , accord standard clinical practice without intervention research purpose . During six month observation patient visit clinic beginning ( day 0 ) , intermediate ( 3 month ) end ( month 6 ) . The purpose visit regularly monitor doctor senile dementia behavior .</brief_summary>
	<brief_title>eVAluatIon OLanzapine TreatmEnT</brief_title>
	<detailed_description>Schizophrenia Treatment may divide follow : Treating first episode- Treatment acute- Maintenance therapy , relapse prevention - Treatment -resistant schizophrenia Treating first episode • The oral antipsychotic ( APS ) second generation ( atypical ) consider treatment choice : olanzapine , risperidone , quetiapine , aripiprazole , ziprasidone , amisulpride , paliperidone - Sertindole use patient tolerate least one remain APS - Advantages monotherapy - The dose medication ( FA ) preferable low limit normal dose define - The appropriate duration therapy continue 12-24 month recession episode . Treatment acute phase . - first-line treatment oral second generation APS . The dos appropriate move within therapeutic range define - For patient receive first-generation APS either reduced efficacy intolerable side effect , treatment choice switch oral second-generation APS - If patient receive first-generation APS good response side effect , remain - The length acute treatment six week less - Where risk increase body weight ( BW ) onset diabetes mellitus ( DM ) treatment atypical APS require close monitoring control routine Investigations - After acute phase high rate relapse , treatment appropriate continue 12-24 month - If determine appropriate treatment discontinuation do gradually close monitoring identify relapse symptom - In case acute psychotic / stimulant patient necessary rapidly quell . In case , oral preparation prefer . If require injectable formulation , drug choice lorazepam , haloperidol , olanzapine , ziprasidone , aripiprazole intramuscular administration . - In case use haloperidol appropriate combine anticholinergic . Is necessary monitor vital sign patient . Maintenance therapy , relapse prevention - If patient benefit acute phase particular FA continue - For oral injectable long-acting antipsychotic use maintenance therapy - For patient receive first-generation APS either reduced efficacy intolerable side effect , treatment choice switch oral second -generation APS - If patient receive first-generation APS good response side effect , remain - Where risk increase OR diabetes treatment atypical antipsychotic closely monitor Investigations routine check even switch another atypical typical APS - If patient happy VAT modify - We prefer monotherapy - The duration therapy appropriate extend 5.2 year patient relapse five year ( perhaps lifelong ) one relapse - If patient receive least two APS ( include one informal ) least 6-8 week without adequate clinical response , consider resistant form disease possibility use clozapine . In case useful add second APS treatment clozapine - Long-acting APS option treatment patient 's wish issue adherence treatment . The long acting formulation prescribe specified limit . resistant schizophrenia - Examine possible factor non-response FA : dose , duration , compliance , substance abuse , physical illness , polypharmacy - If disease refractory treatment standard APS , clinician may initially try use informal APS - If patient receive least two APS ( include one informal ) least 6-8 week without adequate clinical response , consider resistant form disease possibility use clozapine soon possible - In case useful add second APS treatment clozapine . Bipolar I Disorder A. manic / hypomanic mixed EPISODE Step 1 - first choice therapy : lithium , valproate , atypical antipsychotic ( aripiprazole , ziprasidone , quetiapine , olanzapine , risperidone ) , lithium valproate + atypical antipsychotic ( aripiprazole , ziprasidone , quetiapine , olanzapine , risperidone ) without benzodiazepine ( lorazepam ) severe mania - Necessary discontinuation antidepressant . - When select first choice drug take account personal family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , symptom mania ( euphoric , dysphoric , psychotic ) cost . Step 2 ( inadequate response 2 week ) : Optimizing dose control plasma level , compliance check b Change another drug first choice c Add another drug first choice Step 3 ( inadequate response additional 2-4 week ) : change another drug first choice b Start second treatment option : - Conventional antipsychotic ( haloperidol , chlorpromazine ) - Other atypical antipsychotic ( clozapine , paliperidone ) - Lithium valproate + haloperidol - carbamazepine - Lithium + valproate , lithium + carbamazepine - Electroconvulsive Resistant case : - Add change amisulpride , nimodipine Not recommend : - Monotherapy gabapentin , pregabalin , topiramate , lamotrigine , tiagabine , verapamil - Risperidone olanzapine + carbamazepine - Recommended treatment continue least 6-12 month remission . - Strong dose reduction recession tolerate . B. Depressive Episode Step 1 - Cure first choice : - Lithium , lamotrigine , quetiapine - Lithium divalproex + SSRI bupropion , olanzapine + SSRI , lithium + valproate - When select first choice drug take account personal family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , severity depression , suicidality , cost . - Antidepressants , grant , always combine antimanic agent ( lithium , valproate , atypical antipsychotic ) - When coexist psychotic symptom add atypical antipsychotic . Step 2 ( inadequate response 4 week ) : Optimizing dose control plasma level , compliance check b Add change another treatment first choice Step 3 ( inadequate response 4 week ) : change another drug first choice b Start second treatment option : - Quetiapine + SSRI - Valproate , lithium valproate + lamotrigine Step 4 - Treatment option 3 ( inadequate response 4 week ) : - Carbamazepine , lithium + carbamazepine - Olanzapine - Lithium valproate + venlafaxine mirtazapine , lithium valproate atypical antipsychotic + tricyclic antidepressant , lithium + MAO inhibitor - Lithium valproate carbamazepine + SSRI + lamotrigine - Electroconvulsive therapy : particularly patient severe stroke , accompany psychotic catatonic symptom , high risk suicidality , refuse take food , pregnancy may first choice Not recommend : - Monotherapy gabapentin - Monotherapy aripiprazole - Recommended maintenance antidepressant 12 week gradually discontinue within four week unless diversion occur mania hypomania earlier . CAUTION - MAINTENANCE Treatment first choice : - Lithium ( probable good compliance future ) , valproate ( avoided woman childbearing age ) , lamotrigine - Aripiprazole , quetiapine , olanzapine , risperidone risperidone depot - Lithium valproate + quetiapine adjunctive treatment risperidone risperidone depot , additional treatment ziprasidone • Start severe manic episode two episode ( manic , mixed depressive ) - When select first choice drug take account personal family history response treatment , tolerance , contraindication , drug interaction , gender , comorbid condition , compliance history , prevalence manic depressive symptom cost . - ) When prevail manic / hypomanic episode : lithium , valproate , aripiprazole , quetiapine , olanzapine monotherapy combination b ) When prevail depressive episode quetiapine lamotrigine antimanic + ( + antidepressant limit number patient ) Treatment 2nd choice : - carbamazepine - Lithium + valproate , lithium + carbamazepine , lamotrigine , lithium + - Lithium divalproex + olanzapine , lithium + risperidone , olanzapine + fluoxetine Treatment option 3 : - Adjunctive therapy gabapentin - Adjunctive therapy clozapine - Adjunctive therapy omega- 3 fatty acid - Additional maintenance electroconvulsive therapy We recommend : - Monotherapy : gabapentin , topiramate , antidepressants - It recommend continued treatment least 2 year episode illness 5 year risk factor relapse ( substance use , psychotic symptom , history frequent relapse , ongoing stressful life event , poor psychosocial support ) - Recommended continued treatment indefinitely effective prevent recurrence . Anxiety &amp; Related Disorders Generalised Anxiety Disorder Step 1 - Cure first choice : - The SSRIs escitalopram , paroxetine , sertraline SNRIs venlafaxine , duloxetine without benzodiazepine ( alprazolam , diazepam 2-4 week ) - pregabalin - Preferred antidepressant ( SSRIs , SNRIs ) coexist depression . - When select first choice drug take account individual family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , risk suicidality cost . Step 2 ( insufficient response 8-12 week ) : dose increase b change another drug first choice c addition change second drug choice : - quetiapine - Benzodiazepines ( alprazolam , diazepam ) history dependence - hydroxyzine - buspirone Resistant case : - Add another atypical antipsychotic ( olanzapine , risperidone ) - Addition valproate - Addition beta-blocker ( control somatic symptom ) Recommended continued treatment least 6-12 month response . Panic Disorder Step 1 - Cure first choice : - SSRIs ( escitalopram , paroxetine , sertraline , citalopram , fluvoxamine , fluoxetine ) venlafaxine without benzodiazepine ( alprazolam , diazepam , lorazepam 2-4 week ) - Monotherapy benzodiazepine 2-4 week coexist depressive symptom • When select first choice drug take account individual family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , risk suicidality cost . Step 2 ( insufficient response 8-12 week ) : dose increase b change another drug first choice c Treatments second choice : - Switch clomipramine - Addition benzodiazepine ( alprazolam , diazepam , lorazepam ) long period time history dependence Resistant case : - Combination drug first second choice ( eg clomipramine SSRI + venlafaxine ) - Addition atypical antipsychotic - Addition valproate lithium - Addition change mirtazapine - Change moclobemide Recommended continue treatment dose least 12-24 month response . Social Anxiety Disorder ( Social Phobia ) Step 1 - Cure first choice : - SSRIs ( escitalopram , paroxetine , sertraline , citalopram , fluvoxamine , fluoxetine ) venlafaxine without benzodiazepine ( bromazepam , clonazepam 2-4 week ) * When select first choice drug take account individual family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , risk suicidality cost . Step 2 ( insufficient response 8-12 week ) : dose increase b change another drug first choice c Treatments second choice : - Change moclobemide - Addition benzodiazepine ( clonazepam ) long period time history dependence Resistant case : - The first choice drug combination ( eg SSRI + venlafaxine ) - Addition atypical antipsychotic ( olanzapine ) - Addition pregabalin - Addition change mirtazapine - Addition buspirone Recommended continue treatment dose least 6-12 month response . obsessive Compulsive Disorder Step 1 - Cure first choice : - SSRIs ( escitalopram , paroxetine , sertraline , citalopram , fluvoxamine , fluoxetine ) titration maximum tolerate dose - usually need high dos address depression anxiety disorder . - When select first choice drug take account individual family history response treatment , tolerance , contraindication , drug interaction , comorbid condition , risk suicidality cost . Step 2 ( inadequate response 8 12 week , least 4-6 week maximum tolerate dose ) : change another drug first choice b switch clomipramine ( 2nd choice ) Resistant case : - Addition haloperidol atypical antipsychotic ( aripiprazole , quetiapine , olanzapine , risperidone ) - Combination SSRI + clomipramine - Addition change venlafaxine , mirtazapine - Addition lithium - Addition buspirone Recommended continue treatment dose least 12-24 month response . Post Traumatic Stress Disorder 1. st choice : paroxetine , sertraline , fluoxetine venlafaxine • When select first choice drug take account individual family history response treatment , tolerance , contraindication , drug interaction , comorbid condition cost . 2. nd choice : - amitriptyline - mirtazapine - lamotrigine - risperidone Option 3 : - Citalopram , escitalopram , fluvoxamine , moclobemide - Olanzapine , quetiapine - carbamazepine Resistant case : - A combination first second drug choice - Addition olanzapine , risperidone , quetiapine Recommended continue treatment dose least 6-12 month response .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 18 year Diagnosis schizophrenia ( DSMIVDR ) Maintaining clinical improvement continuation therapy patient show initial treatment response . Treatment moderate severe manic episode . Patients whose manic episode respond olanzapine treatment , prevention recurrence patient bipolar disorder ( DSMIV ) The patient reliable caregiver Signed consent form participate study inform reliable caregiver patient witness The patient treat olanzapine joining present study The patient conformability study Hypersensitivity active substance ingredient . Patients know risk narrowangle glaucoma . Dementiarelated psychosis / behavioral disturbance Disease Parkinson Neuroleptic Malignant Syndrome ( NMS ) Patients low leukocyte / neutrophil count reason , patient receive medicine know cause neutropenia , Clinically significant laboratory ECG abnormality . Participation another clinical study Refusal sign consent form participate study inform reliable caregiver patient witness The patient treat olanzapine join clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>olanzapine</keyword>
	<keyword>olanzapine treatment efficacy</keyword>
</DOC>